NCT04853017 - A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 4, 2021

Primary Completion Date

January 26, 2023

Study Completion Date

September 24, 2024

Conditions

Minimal Residual DiseaseKRAS G12DKRAS G12RNRAS G12DNRAS G12RPancreatic Ductal AdenocarcinomaColorectal CancerNon-small Cell Lung CancerOvarian CancerCholangiocarcinomaBile Duct CancerGallbladder Carcinoma

Interventions

DRUG

ELI-002 2P

Amph-CpG-7909 admixed with Amph modified KRAS peptides (Amph-G12D and Amph-G12R) administered via SC injection weekly for 4 consecutive weeks, followed by bi-weekly injections over 4 weeks, during the Immunization Period; additional SC injections weekly for 4 consecutive weeks during the Booster Period (the two periods are separated by 3 months of no dosing)

Trial Locations (10)

10065

Memorial Sloan Kettering Cancer Center, New York

11042

Northwell Health, Lake Success

37203

Tennessee Oncology - Centennial Clinic, Nashville

52242

University of Iowa, Iowa City

63110

Washington University School of Medicine, St Louis

77030

The University of Texas MD Anderson Cancer Center, Houston

80045

University of Colorado, Aurora

90095

University of California Los Angeles, Los Angeles

91010

City of Hope, Duarte

02114

Massachusetts General Hospital, Boston